肿瘤免疫治疗的耐药机制研究进展

Translated title of the contribution: Mechanisms of resistance to cancer immunotherapy

Tingting Zhang, Linyu Li, Zheng Song, Wei Li, Xiubao Ren, Qiang Pan-Hammarström, Kai Fu, Xianhuo Wang, Huilai Zhang

Research output: Contribution to journalArticle

Abstract

Cancer immunotherapy uses the host’s immune system to mobilize immune cells to recognize and eventually eliminate cancer cells. At present, studies in terms of cancer immunotherapy mainly focus on programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) antibody, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, chimeric antigen receptor T-cell immunotherapy (CAR-T), T cell receptor Immunotherapy (TCR-T), etc. Despite the fact that cancer immunotherapies elicit unprecedented durable responses in clinical therapy, they appear to be ineffective to some patients. In addition, some responders relapse and show resistance to immunotherapies even if their symptoms are relieved for a time. Resistance to cancer immunotherapy can be categorized into primary, adaptive and acquired, which can occur in every stage during the process of anti-tumor response. In this review, we discuss the known mechanisms of resistance and provide a rationale for the use of combination therapy to overcome resistance.

Original languageChinese
Pages (from-to)874-878
Number of pages5
JournalChinese Journal of Microbiology and Immunology (China)
Volume37
Issue number11
DOIs
StatePublished - Nov 30 2017

    Fingerprint

Keywords

  • Immune checkpoint
  • Immunotherapy
  • Resistance mechanism

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Virology

Cite this

Zhang, T., Li, L., Song, Z., Li, W., Ren, X., Pan-Hammarström, Q., Fu, K., Wang, X., & Zhang, H. (2017). 肿瘤免疫治疗的耐药机制研究进展. Chinese Journal of Microbiology and Immunology (China), 37(11), 874-878. https://doi.org/10.3760/cma.j.issn.0254-5101.2017.11.012